MetaCap

Galectin Therapeutics (GALT) vs Turn Therapeutics (TTRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.

Summary

Turn Therapeutics is the larger company by market cap ($367.4 million vs $365.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Head-to-head

GALT versus TTRX key metrics
MetricGALTTTRX
Share price$3.62$12.10
Market cap$365.08M$367.45M
1-day change-3.72%+3.95%
YTD return-12.98%—
1-year return-24.11%—
5-year return+7.42%—
EPS (TTM)$-0.43$-0.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$7.13$26.50
52-week low$2.03$2.57
Distance from 52-week high-49.23%-54.34%
Average volume387.94K114.62K
Shares outstanding100.85M30.37M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

GALT vs TTRX FAQ

Which is bigger, Galectin Therapeutics or Turn Therapeutics?

Turn Therapeutics (TTRX) is larger, with a market capitalization of $367.45M compared with $365.08M for Galectin Therapeutics (GALT).

Are Galectin Therapeutics and Turn Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons